The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'June, 2019'. If you still can't find what you are looking for, try using the search box.
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD).
Read the rest of entry »
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019
24 June 2019: Treatment of diseases of the back of the eye such as age-related macular degeneration (AMD) and diabetic eye disease is set to be improved with a €4m EU-funded project led by Waterford Institute of Technology (WIT) in partnership with the University of Birmingham.
ScreenIn3D, a partner of AMSBIO, has received a share of the £1 million plus prize pot and will receive ongoing support from partners of Scottish Edge - a respected regional business support agency.
SAN FRANCISCO--(BUSINESS WIRE)--Jun. 17, 2019-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist Mouse Core Exome Panel, the most comprehensive, up-to-date tool for interrogation of the mouse exome, further enabling genetic research of this important model organism.
Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019
The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging.
7th June 2019: NASA scientists and astronauts will visit the University of Birmingham to discuss how drug discoveries in NHS patients could reduce brain pressure during space travel to allow them to go beyond the Moon.
Aigenpulse is proud to announce the latest release of our Machine Learning Platform that brings advanced analytics to scientists, enabling data driven decision making!
The Electrospinning Company, first established in 2010 as a spin-out from research undertaken by the UK Science and Technology Facilities Council (STFC), has received £1.5 million new funding led by London-based venture capital firm Downing Ventures, alongside VC firm MidVen, Newable Private Investing and the STFC.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.